10.As provided in the rules, surrogate marker should be considered as an interim data point and further clinical data should be generated following the approval of the new drug based on surrogate marker consideration that must unequivocally support the patients benefit. 11.Upon receipt of NDA the CDSCO should review the application to determine its completeness within timeline to be prescribed wit ...

Accredited Consultants Pvt. Ltd We are an ISO 10002:2004, ISO 9001:2008 Company and India’s most trusted management consulting firm with over 15 years of experience in the business. We collaborate with visionary leaders, institutions, ministries, research organizations & regulatory bodies from all sectors and spectrum to help you enter India’s vibrant market with most suited and in-depth strategy ...